{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:48:57Z","timestamp":1794048537303,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R223-2015-4222"],"award-info":[{"award-number":["R223-2015-4222"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R248-2016-2518"],"award-info":[{"award-number":["R248-2016-2518"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1176607"],"award-info":[{"award-number":["1176607"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012769","name":"Neuroscience Research Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["Distinguished Innovator 1-2020 grant"],"award-info":[{"award-number":["Distinguished Innovator 1-2020 grant"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU Multinational research projects on Personalised Medicine for Neurodegenerative Diseases","award":["JPND2019"],"award-info":[{"award-number":["JPND2019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Synucleinopathies are characterized by neurodegeneration and deposition of the presynaptic protein \u03b1-synuclein in pathological protein inclusions. Growing evidence suggests the complement system not only has physiological functions in the central nervous system, but also is involved in mediating the pathological loss of synapses in Alzheimer\u2019s disease. However, it is not established whether the complement system has a similar role in the diseases Parkinson's disease, Dementia with Lewy bodies, and multiple system atrophy (MSA) that are associated with \u03b1-synuclein aggregate pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To investigate if the complement system has a pathological role in synucleinopathies, we assessed the effect of the complement system on the viability of an \u03b1-synuclein expressing cell model and examined direct activation of the complement system by \u03b1-synuclein in a plate-based activation assay. Finally, we investigated the levels of the initiator of the classical pathway, C1q, in postmortem brain samples from MSA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrate that \u03b1-synuclein activates the classical complement pathway and mediates complement-dependent toxicity in \u03b1-synuclein expressing SH-SY5Y cells. The \u03b1-synuclein-dependent cellular toxicity was rescued by the complement inhibitors RaCI (inhibiting C5) and Cp20 (inhibiting C3). Furthermore, we observed a trend for higher levels of C1q in the putamen of MSA subjects than that of controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\u03b1-Synuclein can activate the classical complement pathway, and the complement system is involved in \u03b1-synuclein-dependent cellular cytotoxicity suggesting the system could play a prodegenerative role in synucleinopathies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-021-02225-9","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T10:04:08Z","timestamp":1629108248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity"],"prefix":"10.1186","volume":"18","author":[{"given":"Emil","family":"Gregersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Betzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woojin S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergo","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda M.","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4439-9020","authenticated-orcid":false,"given":"Poul Henning","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"20","key":"2225_CR1","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1523\/jneurosci.22-20-08797.2002","volume":"22","author":"DE Cabin","year":"2002","unstructured":"Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking \u03b1-synuclein. J Neurosci. 2002;22(20):8797\u2013807. https:\/\/doi.org\/10.1523\/jneurosci.22-20-08797.2002.","journal-title":"J Neurosci"},{"issue":"5","key":"2225_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nn.4529","volume":"20","author":"T Logan","year":"2017","unstructured":"Logan T, Bendor J, Toupin C, Thorn K, Edwards RH. \u03b1-Synuclein promotes dilation of the exocytotic fusion pore. Nat Neurosci. 2017;20(5):681\u20139. https:\/\/doi.org\/10.1038\/nn.4529.","journal-title":"Nat Neurosci"},{"issue":"4","key":"2225_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1353-8020(99)00031-0","volume":"5","author":"MG Spillantini","year":"1999","unstructured":"Spillantini MG. Parkinson\u2019s disease, dementia with Lewy bodies and multiple system atrophy are \u03b1-synucleinopathies. Parkinsonism Relat Disord. 1999;5(4):157\u201362. https:\/\/doi.org\/10.1016\/S1353-8020(99)00031-0.","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"2225_CR4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/sj.mp.4000458","volume":"3","author":"M Goedert","year":"1998","unstructured":"Goedert M, Spillantini MG. Lewy body diseases and multiple system atrophy as \u03b1-synucleinopathies. Mol Psychiatry. 1998;3(6):462\u20135. https:\/\/doi.org\/10.1038\/sj.mp.4000458.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"2225_CR5","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L. \u03b1-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2(2):a009399. https:\/\/doi.org\/10.1101\/cshperspect.a009399.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"2225_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211. https:\/\/doi.org\/10.1016\/S0197-4580(02)00065-9.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"2225_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"J-Y Li","year":"2008","unstructured":"Li J-Y, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501\u20133. https:\/\/doi.org\/10.1038\/nm1746.","journal-title":"Nat Med"},{"issue":"16","key":"2225_CR8","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/mds.22369","volume":"23","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008;23(16):2303\u20136. https:\/\/doi.org\/10.1002\/mds.22369.","journal-title":"Mov Disord"},{"issue":"8","key":"2225_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/wnl.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology. 1988;38(8):1285\u201391. https:\/\/doi.org\/10.1212\/wnl.38.8.1285.","journal-title":"Neurology."},{"issue":"1","key":"2225_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1172\/JCI36470","volume":"119","author":"V Brochard","year":"2009","unstructured":"Brochard V, Combadi\u00e8re B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119(1):182\u201392. https:\/\/doi.org\/10.1172\/JCI36470.","journal-title":"J Clin Invest"},{"issue":"6","key":"2225_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.20682","volume":"58","author":"H Chen","year":"2005","unstructured":"Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson\u2019s disease. Ann Neurol. 2005;58(6):963\u20137. https:\/\/doi.org\/10.1002\/ana.20682.","journal-title":"Ann Neurol"},{"issue":"12","key":"2225_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","volume":"74","author":"JJ Gagne","year":"2010","unstructured":"Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology. 2010;74(12):995\u20131002. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d5a4a3.","journal-title":"Neurology."},{"issue":"12","key":"2225_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","volume":"20","author":"JJ Sabatino","year":"2019","unstructured":"Sabatino JJ, Pr\u00f6bstel AK, Zamvil SS. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci. 2019;20(12):728\u201345. https:\/\/doi.org\/10.1038\/s41583-019-0233-2.","journal-title":"Nat Rev Neurosci"},{"issue":"22","key":"2225_CR14","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.15252\/embj.201591881","volume":"34","author":"G Bajic","year":"2015","unstructured":"Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J. 2015;34(22):2735\u201357. https:\/\/doi.org\/10.15252\/embj.201591881.","journal-title":"EMBO J"},{"issue":"24","key":"2225_CR15","doi-asserted-by":"publisher","first-page":"14469","DOI":"10.1016\/S0021-9258(18)77326-2","volume":"265","author":"NM Thielens","year":"1990","unstructured":"Thielens NM, Aude CA, Lacroix MB, Gagnon J, Arlaud GJ. Ca2+ binding properties and Ca2+-dependent interactions of the isolated NH2-terminal \u03b1 fragments of human complement proteases C1\u0304r and C1\u0304s. J Biol Chem. 1990;265(24):14469\u201375. https:\/\/doi.org\/10.1016\/S0021-9258(18)77326-2.","journal-title":"J Biol Chem"},{"issue":"6","key":"2225_CR16","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","volume":"131","author":"B Stevens","year":"2007","unstructured":"Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131(6):1164\u201378. https:\/\/doi.org\/10.1016\/j.cell.2007.10.036.","journal-title":"Cell."},{"key":"2225_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.aad8373","volume":"8373","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;8373:1\u20139. https:\/\/doi.org\/10.1126\/science.aad8373.","journal-title":"Science"},{"issue":"1","key":"2225_CR18","doi-asserted-by":"publisher","first-page":"11.900886","DOI":"10.1101\/2020.01.11.900886","volume":"2020","author":"SX Ma","year":"2020","unstructured":"Ma SX, Kim D, Xiong Y, et al. Complement and coagulation cascades are potentially involved in dopaminergic neurodegeneration in \u03b1-synuclein-based mouse models of Parkinson\u2019s disease. bioRxiv. 2020;2020(1):11.900886. https:\/\/doi.org\/10.1101\/2020.01.11.900886.","journal-title":"bioRxiv"},{"issue":"1","key":"2225_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/BF00427222","volume":"84","author":"T Yamada","year":"1992","unstructured":"Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson\u2019s disease are recognized by antibodies to complement proteins. Acta Neuropathol. 1992;84(1):100\u20134. https:\/\/doi.org\/10.1007\/BF00427222.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2225_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1155\/2005\/806573","volume":"21","author":"EJ Finehout","year":"2005","unstructured":"Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers. 2005;21(2):93\u2013101. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3851089&tool=pmcentrez&rendertype=abstract. https:\/\/doi.org\/10.1155\/2005\/806573.","journal-title":"Dis Markers"},{"issue":"4","key":"2225_CR21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ajpath.2011.01.006","volume":"178","author":"Y Wang","year":"2011","unstructured":"Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, et al. Complement 3 and factor H in human cerebrospinal fluid in Parkinson\u2019s disease, Alzheimer\u2019s disease, and multiple-system atrophy. Am J Pathol. 2011;178(4):1509\u201316. https:\/\/doi.org\/10.1016\/j.ajpath.2011.01.006.","journal-title":"Am J Pathol"},{"issue":"2","key":"2225_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0116473","volume":"10","author":"C Betzer","year":"2015","unstructured":"Betzer C, Movius AJ, Shi M, Gai WP, Zhang J, Jensen PH. Identification of synaptosomal proteins binding to monomeric and oligomeric \u03b1-synuclein. PLoS One. 2015;10(2):1\u201324. https:\/\/doi.org\/10.1371\/journal.pone.0116473.","journal-title":"PLoS One"},{"issue":"2","key":"2225_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0022-1759(83)90035-2","volume":"59","author":"F Joisel","year":"1983","unstructured":"Joisel F, Leroux-Nicollet I, Lebreton JP, Fontaine M. A hemolytic assay for clinical investigation of human C2. J Immunol Methods. 1983;59(2):229\u201335. https:\/\/doi.org\/10.1016\/0022-1759(83)90035-2.","journal-title":"J Immunol Methods"},{"issue":"NOV","key":"2225_CR24","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","volume":"9","author":"MG Da Costa","year":"2018","unstructured":"Da Costa MG, Poppelaars F, Van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. Front Immunol. 2018;9(NOV):2664. https:\/\/doi.org\/10.3389\/fimmu.2018.02664.","journal-title":"Front Immunol"},{"issue":"7","key":"2225_CR25","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1074\/jbc.M410409200","volume":"280","author":"E Lindersson","year":"2005","unstructured":"Lindersson E, Lundvig D, Petersen C, Madsen P, Nyengaard JR, H\u00f8jrup P, et al. p25\u03b1 stimulates \u03b1-synuclein aggregation and is co-localized with aggregated \u03b1-synuclein in \u03b1-synucleinopathies. J Biol Chem. 2005;280(7):5703\u201315. https:\/\/doi.org\/10.1074\/jbc.M410409200.","journal-title":"J Biol Chem"},{"issue":"36","key":"2225_CR26","doi-asserted-by":"publisher","first-page":"25481","DOI":"10.1074\/jbc.274.36.25481","volume":"274","author":"PH Jensen","year":"1999","unstructured":"Jensen PH, Hager H, Nielsen MS, H\u00f8jrup P, Gliemann J, Jakes R. \u03b1-synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem. 1999;274(36):25481\u20139. https:\/\/doi.org\/10.1074\/jbc.274.36.25481.","journal-title":"J Biol Chem"},{"issue":"2","key":"2225_CR27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4049\/jimmunol.127.2.648","volume":"127","author":"A Tenner","year":"1981","unstructured":"Tenner A, Lesavre P, Cooper N. Purification and radiolabeling of human C1q. J Immunol. 1981;127(2):648\u201353 http:\/\/www.jimmunol.org\/content\/127\/2\/648.short. Accessed June 16, 2014.","journal-title":"J Immunol"},{"issue":"5","key":"2225_CR28","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1471-4159.2009.06054.x","volume":"109","author":"K Vekrellis","year":"2009","unstructured":"Vekrellis K, Xilouri M, Emmanouilidou E, Stefanis L. Inducible over-expression of wild type \u03b1-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. J Neurochem. 2009;109(5):1348\u201362. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06054.x.","journal-title":"J Neurochem"},{"key":"2225_CR29","doi-asserted-by":"publisher","unstructured":"Betzer C, Lassen LB, Olsen A, et al. Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. EMBO Rep. 2018;e44617. https:\/\/doi.org\/10.15252\/embr.201744617.","DOI":"10.15252\/embr.201744617"},{"issue":"1","key":"2225_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0022-1759(93)90240-8","volume":"163","author":"GJ Wolbink","year":"1993","unstructured":"Wolbink GJ, Bollen J, Baars JW, ten Berge RJM, Swaak AJG, Paardekooper J, et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods. 1993;163(1):67\u201376. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7687639. https:\/\/doi.org\/10.1016\/0022-1759(93)90240-8.","journal-title":"J Immunol Methods"},{"key":"2225_CR31","doi-asserted-by":"publisher","unstructured":"Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19(12). https:\/\/doi.org\/10.1002\/mds.20255.","DOI":"10.1002\/mds.20255"},{"issue":"1","key":"2225_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-014-0150-6","volume":"2","author":"AS Don","year":"2014","unstructured":"Don AS, Hsiao JHT, Bleasel JM, Couttas TA, Halliday GM, Kim WS. Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathol Commun. 2014;2(1):1\u201314. https:\/\/doi.org\/10.1186\/s40478-014-0150-6.","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"2225_CR33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nsmb.3196","volume":"23","author":"MM Jore","year":"2016","unstructured":"Jore MM, Johnson S, Sheppard D, Barber NM, Li YI, Nunn MA, et al. Structural basis for therapeutic inhibition of complement C5. Nat Struct Mol Biol. 2016;23(5):378\u201386. https:\/\/doi.org\/10.1038\/nsmb.3196.","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"2225_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/eci.12419","volume":"45","author":"DC Mastellos","year":"2015","unstructured":"Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Investig. 2015;45(4):423\u201340. https:\/\/doi.org\/10.1111\/eci.12419.","journal-title":"Eur J Clin Investig"},{"issue":"4","key":"2225_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.neuron.2012.03.026","volume":"74","author":"DP Schafer","year":"2012","unstructured":"Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74(4):691\u2013705. https:\/\/doi.org\/10.1016\/j.neuron.2012.03.026.","journal-title":"Neuron."},{"key":"2225_CR36","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.redox.2017.11.010","volume":"14","author":"L Hou","year":"2018","unstructured":"Hou L, Bao X, Zang C, Yang H, Sun F, Che Y, et al. Integrin CD11b mediates \u03b1-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway. Redox Biol. 2018;14:600\u20138. https:\/\/doi.org\/10.1016\/j.redox.2017.11.010.","journal-title":"Redox Biol"},{"key":"2225_CR37","doi-asserted-by":"publisher","unstructured":"Stephan A. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev. 2012. https:\/\/doi.org\/10.1146\/annurev-neuro-061010.","DOI":"10.1146\/annurev-neuro-061010"},{"issue":"1","key":"2225_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1742-2094-3-29","volume":"3","author":"DA Loeffler","year":"2006","unstructured":"Loeffler DA, Camp DM, Conant SB. Complement activation in the Parkinson\u2019s disease substantia nigra: an immunocytochemical study. J Neuroinflammation. 2006;3(1):29. https:\/\/doi.org\/10.1186\/1742-2094-3-29.","journal-title":"J Neuroinflammation"},{"issue":"6307","key":"2225_CR39","doi-asserted-by":"publisher","first-page":"aah3374","DOI":"10.1126\/science.aah3374","volume":"353","author":"X Mao","year":"2016","unstructured":"Mao X, Ou MT, Karuppagounder SS, et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353(6307):aah3374. https:\/\/doi.org\/10.1126\/science.aah3374.","journal-title":"Science"},{"issue":"1","key":"2225_CR40","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/ncomms2534","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, et al. Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4(1):1562. https:\/\/doi.org\/10.1038\/ncomms2534.","journal-title":"Nat Commun"},{"issue":"2","key":"2225_CR41","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.ajpath.2011.04.013","volume":"179","author":"N Stefanova","year":"2011","unstructured":"Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-like receptor 4 promotes \u03b1-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol. 2011;179(2):954\u201363. https:\/\/doi.org\/10.1016\/j.ajpath.2011.04.013.","journal-title":"Am J Pathol"},{"key":"2225_CR42","doi-asserted-by":"publisher","unstructured":"Surguchev AA, Emamzadeh FN, Surguchov A. Cell responses to extracellular \u03b1-synuclein. Molecules. 2019;24(2). https:\/\/doi.org\/10.3390\/molecules24020305.","DOI":"10.3390\/molecules24020305"},{"issue":"11","key":"2225_CR43","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/nn.4648","volume":"20","author":"DG Ferreira","year":"2017","unstructured":"Ferreira DG, Temido-Ferreira M, Miranda HV, et al. \u03b1-synuclein interacts with PrP C to induce cognitive impairment through mGluR5 and NMDAR2B. Nat Neurosci. 2017;20(11):1569\u201379. https:\/\/doi.org\/10.1038\/nn.4648.","journal-title":"Nat Neurosci"},{"issue":"30","key":"2225_CR44","doi-asserted-by":"publisher","first-page":"10427","DOI":"10.1073\/pnas.0502066102","volume":"102","author":"A Quist","year":"2005","unstructured":"Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A. 2005;102(30):10427\u201332. https:\/\/doi.org\/10.1073\/pnas.0502066102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2225_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1326-7-42","volume":"7","author":"KM Danzer","year":"2012","unstructured":"Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7(1):42. https:\/\/doi.org\/10.1186\/1750-1326-7-42.","journal-title":"Mol Neurodegener"},{"issue":"3-4","key":"2225_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2119\/molmed.2010.00149","volume":"17","author":"C Ehrnthaller","year":"2011","unstructured":"Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med. 2011;17(3-4):317\u201329. https:\/\/doi.org\/10.2119\/molmed.2010.00149.","journal-title":"Mol Med"},{"issue":"1","key":"2225_CR47","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/JLB.3MIR0220-270R","volume":"108","author":"MW Lo","year":"2020","unstructured":"Lo MW, Woodruff TM. Complement: bridging the innate and adaptive immune systems in sterile inflammation. J Leukoc Biol. 2020;108(1):339\u201351. https:\/\/doi.org\/10.1002\/JLB.3MIR0220-270R.","journal-title":"J Leukoc Biol"},{"issue":"4","key":"2225_CR48","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/jnr.490400407","volume":"40","author":"DG Walker","year":"1995","unstructured":"Walker DG, Kim SU, McGeer PL. Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res. 1995;40(4):478\u201393. https:\/\/doi.org\/10.1002\/jnr.490400407.","journal-title":"J Neurosci Res"},{"issue":"4","key":"2225_CR49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/glia.10234","volume":"42","author":"M Hosokawa","year":"2003","unstructured":"Hosokawa M, Klegeris A, Maguire J, McGeer PL. Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia. 2003;42(4):417\u201323. https:\/\/doi.org\/10.1002\/glia.10234.","journal-title":"Glia."},{"issue":"2","key":"2225_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0006-8993(97)00850-0","volume":"769","author":"Y Shen","year":"1997","unstructured":"Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997;769(2):391\u20135. https:\/\/doi.org\/10.1016\/S0006-8993(97)00850-0.","journal-title":"Brain Res"},{"issue":"4","key":"2225_CR51","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.bbrc.2007.04.055","volume":"357","author":"A Klegeris","year":"2007","unstructured":"Klegeris A, McGeer PL. Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. Biochem Biophys Res Commun. 2007;357(4):1096\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2007.04.055.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"2225_CR52","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","volume":"18","author":"DC Mastellos","year":"2019","unstructured":"Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019;18(9):707\u201329. https:\/\/doi.org\/10.1038\/s41573-019-0031-6.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02225-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-021-02225-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-021-02225-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T07:44:18Z","timestamp":1673077458000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-021-02225-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2225"],"URL":"https:\/\/doi.org\/10.1186\/s12974-021-02225-9","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"12 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval (HC16568) was from the University of New South Wales Human Research Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}